RxDoctor Payments Data

Annelise Gauthier

Gerontology · Grand Rapids, MINPI 1740933886

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by GSK at 37.5% of the total. Reporting peaked in 2024 at $1,109 and has fallen 71.0% since, to $322 in 2025.

$2,369in general payments, 2019–2025

Across 25 payments — averaging $94.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$887
  • Myriad Genetic Laboratories, Inc.$253
  • AbbVie$231
  • AstraZeneca$211
  • Seagen Inc.$179
  • Tactile Systems Technology Inc$143
  • plus $465 from 5 others

What the payments were for

  • Food & beverage$2,369100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,369 in reported general payments places this provider in the 85th percentile of 279 gerontology providers in Michigan.

See all gerontology providers in Michigan

Medicare billing

Part B allowed, 2024
$21,293
Medicare patients
103
Services billed
225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$27,855
Letrozole34$888
Clobetasol Propionate27$473
Gabapentin22$199
Nystatin13$165
Escitalopram Oxalate23$156
Lidocaine-PrilocaineLidocaine/Prilocaine12$132
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$119
Ondansetron OdtOndansetron13$100
Ondansetron Hcl18$99
Prednisone13$20
Oxycodone Hcl13$16

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$120$27,85551 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 279 gerontology providers in Michigan.

Other gerontology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →